GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

APL-2301   Click here for help

GtoPdb Ligand ID: 13957

Synonyms: ASN-1733 | MET-102
Compound class: Synthetic organic
Comment: APL-2301 is a nitroxoline derivative with broad-spectrum antibacterial activity [2]. It is being developed to target infections caused by Acinetobacter baumannii.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 75.73
Molecular weight 303.5
XLogP 2.99
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CN=C2C(=C1)C(=C(C(=C2O)[N+](=O)[O-])Br)Cl
Isomeric SMILES C1=CC2=C(C(=C(C(=C2Cl)Br)[N+](=O)[O-])O)N=C1
InChI InChI=1S/C9H4BrClN2O3/c10-5-6(11)4-2-1-3-12-7(4)9(14)8(5)13(15)16/h1-3,14H
InChI Key BZGYNSYRIWILNU-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Asieris Pharmaceuticals. 
APL-2301, a FIC small molecule developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia.
Accessed on 17/06/2025. Modified on 17/06/2025. https://asieris.com/apl-2301-a-compound-developed-by-asieris-for-the-treatment-of-acinetobacter-baumannii-infection-was-approved-for-phase-i-clinical-trials-in-australia/
2. He P, Huang S, Wang R, Yang Y, Yang S, Wang Y, Qi M, Li J, Liu X, Zhang X et al.. (2024)
Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition.
Emerg Microbes Infect, 13 (1): 2294854. [PMID:38085067]